Sign in

Biosimilars vs. Biologics: Market Comparison 2022-2029

Aishwarya Bhasme
Biosimilars vs. Biologics: Market Comparison 2022-2029

Biosimilar Market was valued at US$ 19.19 Bn. in 2021. The Global Biosimilar Market size is estimated to grow at a CAGR of 34.5% over the forecast period.

Biosimilar Market Overview: 

Maximize Market Research's new report, Global Biosimilar Market 2021-2027, is useful for understanding the market's competitors. The research provides a broad and basic examination of the market, including an examination of subjective factors that might provide readers with vital business insights. The research provides a market overview that explains the value chain structure, geographical analysis, applications, market size, and forecast (2021-2027). The research will serve as a vehicle for a more accurate assessment of the current and future conditions of the worldwide Biosimilar market.

For detail insights on this market, request for methodology here


Biosimilar Market Scope:

The research provides an analytical view of the business by studying several elements such as worldwide Biosimilar market growth, consumption volume, market trends, and company pricing structures throughout the projected period. The analysis includes extensive research to explore the market's complexities. The research provides an overview of the worldwide Biosimilar market, including market characteristics, market segmentation analysis, market size, customer landscape, and geographical landscape. The study considers growth drivers, current trends, advancements, prospects, and the competitive environment in its research. This market has been examined in several areas based on productivity and manufacturing base.

Biosimilar Market Segmentation: 

The quickest-rising In 2021, monoclonal antibodies held a dominant share of the biosimilar market in the United States. The early patent expiration of monoclonal antibodies has led to the development of biosimilars, which are copies of the original drug's active ingredients. The first biosimilar monoclonal antibody authorized for use in oncology was called Truxima.

During the projected time, filgrastim and pegfilgrastim are expected to have the second-largest segment. The introduction of biosimilar filgrastim acting granulocyte colony-stimulating factor has revolutionized patient access by providing cost-effective prevention of FN with a definite clinical benefit. Pegfilgrastim's launch presents chances for biosimilar filgrastim users to increase adherence and generate financial gains for the nations that use reference pegfilgrastim.

1. Global Biosimilar Market Size, by Drug Class Analysis (2021-2029)

• Monoclonal antibodies

• Filgrastim and pegfilgrastim

2. Global Biosimilar Market Size, by therapies (2021-2029)

• Autoimmune

• Oncology

• Diabetes

• Anticoagulant

• Central nervous system

• Respiratory


3. Global Biosimilar Market Size, by Binder Type (2021-2029)

• Emulsion Bonded Glass Mat

• Powder Bonded Glass Mat

For any Queries Linked with the Report, Ask an Analyst


Biosimilar Market Key Players:

It then discusses the top competitors in the worldwide Biosimilar market, as well as emerging players, in detail, including market share based on revenue, demand, high-quality product makers, sales, and service providers. In addition, the research assesses capacity utilization, raw material sources, import-export, the value chain, price structure, and the industrial supply chain. The following players are featured in this report:

• Pfizer

• Amgen

• Biocon

• Dr. Reddy’s Laboratories

• Celltrion

• Samsung Biologics

• Eli Lily & Company

• Hospira Inc.

• Ctavis, Inc

• Teva Pharmaceutical Industries Ltd.

• Cipla Ltd.

• Stada Arzneimittel Ag

• Wockhardt Ltd

• Mylan, Inc.

• Biocad

• Coherus Bioscience

• Boehringer Ingelheim

• Fresenius Kabi AG

For any Queries Linked with the Report, Ask an Analyst


Regional Analysis:

The report has analyzed the global Biosimilar market in the following regions:

  • America, North (the United States, Canada, and Mexico)
  • European Union (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific region (China, Japan, Korea, India, Southeast Asia, and Australia)
  • Latin America (Brazil, Argentina, Colombia, and Rest of South America)
  • Africa and the Middle East (Saudi Arabia, UAE, Egypt, South Africa, and Rest of the Middle East & Africa)

The research provides comprehensive insights into numerous development opportunities and challenges in the regions mentioned above based on various types of goods, applications, end-users, and countries, among others. The research also includes key features of the worldwide Biosimilar market, such as sales growth, product price and analysis, growth potential, and suggestions for tackling market issues in the given regions.

COVID-19 Impact Analysis on Biosimilar Market:

COVID-19 is an unprecedented worldwide public health emergency that has impacted practically every business, and the long-term impacts are expected to have an influence on industry growth throughout the projection period. Our continuing study expands our research methodology to include fundamental COVID-19 concerns and potential next steps. The research provides insights on COVID-19 by taking into account changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, the dynamics of contemporary market forces, and substantial government initiatives. The revised report contains insights, analysis, projections, and predictions based on the influence of COVID-19 on the market.

Key Questions Answered in the Biosimilar Market Report are: 

  • Which are the major companies in the Biosimilar market? 
  • Which is the potential market for Biosimilar in terms of the region?
  • Which application area of Biosimilar is expected to grow at a significant rate in the market in the next 5 years?
  • What are the opportunities for new market entrants?
  • What will be the Biosimilar market size by 2027?
  • What are the growth prospects for the Biosimilar market?
  • What is the base year considered in the Biosimilar market report?
  • Which region holds the largest market share in the Biosimilar market?
  • What factors are anticipated to drive the Biosimilar market? 

About Us

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

Our Address

  • ⮝ 444 West Lake Street, Floor 17,
  •     Chicago, IL, 60606, USA.
  • ✆ +1 800 507 4489
  • ✆ +91 9607365656
  • 🖂 [email protected]

Aishwarya Bhasme
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more